siRNA and chemotherapeutic molecules entrapped into a redox-responsive platform for targeted synergistic combination therapy of glioma

Wen, Liang; Wen, Changlong; Zhang, Fengtian; Wang, Kai; Yuan, Hong; Hu, Fuqiang

doi:10.1016/j.nano.2020.102218

Cited by 18 publications

(15 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This system achieved synergistic anti-EGFR activity in that Gefitinib markedly inhibited EGFR signaling, while GOLPH3 silencing promoted EGFR and p-EGFR degradation [131]. In line with the use of polymers for the design of dual agent nanostructures, Wen and coworkers [132] reported on an Angiopep-2 decorated glycolipid-like co-polymeric micelle for the simultaneous delivery of VEGF siRNA and paclitaxel in vivo.…”

Section: Drug and Nucleic Acid Co-deliverymentioning

confidence: 93%

Angiopep-2-Modified Nanoparticles for Brain-Directed Delivery of Therapeutics: A Review

Habib

Singh

2022

Polymers

View full text Add to dashboard Cite

Nanotechnology has opened up a world of possibilities for the treatment of brain disorders. Nanosystems can be designed to encapsulate, carry, and deliver a variety of therapeutic agents, including drugs and nucleic acids. Nanoparticles may also be formulated to contain photosensitizers or, on their own, serve as photothermal conversion agents for phototherapy. Furthermore, nano-delivery agents can enhance the efficacy of contrast agents for improved brain imaging and diagnostics. However, effective nano-delivery to the brain is seriously hampered by the formidable blood–brain barrier (BBB). Advances in understanding natural transport routes across the BBB have led to receptor-mediated transcytosis being exploited as a possible means of nanoparticle uptake. In this regard, the oligopeptide Angiopep-2, which has high BBB transcytosis capacity, has been utilized as a targeting ligand. Various organic and inorganic nanostructures have been functionalized with Angiopep-2 to direct therapeutic and diagnostic agents to the brain. Not only have these shown great promise in the treatment and diagnosis of brain cancer but they have also been investigated for the treatment of brain injury, stroke, epilepsy, Parkinson’s disease, and Alzheimer’s disease. This review focuses on studies conducted from 2010 to 2021 with Angiopep-2-modified nanoparticles aimed at the treatment and diagnosis of brain disorders.

show abstract

Section: Drug and Nucleic Acid Co-deliverymentioning

confidence: 93%

Angiopep-2-Modified Nanoparticles for Brain-Directed Delivery of Therapeutics: A Review

Habib

Singh

2022

Polymers

View full text Add to dashboard Cite

show abstract

“…Recently, nanomaterials have been extensively applied in life science, energy science and other fields (Xu et al, 2019;Zhuang et al, 2019;Kuang et al, 2020;Wen et al, 2020;Chen et al, 2021;He et al, 2021;Liu et al, 2021;Savchenko et al, 2021;Schultz et al, 2021;Wu et al, 2021;Xu and Liu, 2021;He et al, 2022;Yi et al, 2022;Zhuang et al, 2022). At present, nanomaterials in electrochemical biosensors have also been broadly concerned for gauging SARS-COV-2.…”

Section: Specific Detection Of Sars-cov-2 Nucleic Acidmentioning

confidence: 99%

Recent Progresses in Electrochemical DNA Biosensors for SARS-CoV-2 Detection

Mei

Lin

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Coronavirus disease 19 (COVID-19) is still a major public health concern in many nations today. COVID-19 transmission is now controlled mostly through early discovery, isolation, and therapy. Because of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the contributing factor to COVID-19, establishing timely, sensitive, accurate, simple, and budget detection technologies for the SARS-CoV-2 is urgent for epidemic prevention. Recently, several electrochemical DNA biosensors have been developed for the rapid monitoring and detection of SARS-CoV-2. This mini-review examines the latest improvements in the detection of SARS-COV-2 utilizing electrochemical DNA biosensors. Meanwhile, this mini-review summarizes the problems faced by the existing assays and puts an outlook on future trends in the development of new assays for SARS-CoV-2, to provide researchers with a borrowing role in the generation of different assays.

show abstract

“…Researchers developed an angiopep-2 (Ap) modified redox-responsive glycolipid-like copolymer co-delivering siVEGF and paclitaxel (PTX). These copolymers are superior in suppressing glioma growth via receptor-mediated targeting delivery and cell apoptosis, accompanied by an evident inhibition of neovascularization induced by VEGF (Wen et al, 2020). YAP is a transcription co-activator of the Hippo Pathway and plays an essential role in regulating cell proliferation and apoptosis (Ma et al, 2016).…”

Section: Co-delivery Of Small Interfering Rna and Anti-cancer Compoundsmentioning

confidence: 99%

Small Interfering RNA for Gliomas Treatment: Overcoming Hurdles in Delivery

Teng

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Gliomas are central nervous system tumors originating from glial cells, whose incidence and mortality rise in coming years. The current treatment of gliomas is surgery combined with chemotherapy or radiotherapy. However, developing therapeutic resistance is one of the significant challenges. Recent research suggested that small interfering RNA (siRNA) has excellent potential as a therapeutic to silence genes that are significantly involved in the manipulation of gliomas’ malignant phenotypes, including proliferation, invasion, metastasis, therapy resistance, and immune escape. However, it is challenging to deliver the naked siRNA to the action site in the cells of target tissues. Therefore, it is urgent to develop delivery strategies to transport siRNA to achieve the optimal silencing effect of the target gene. However, there is no systematic discussion about siRNAs’ clinical potential and delivery strategies in gliomas. This review mainly discusses siRNAs’ delivery strategies, especially nanotechnology-based delivery systems, as a potential glioma therapy. Moreover, we envisage the future orientation and challenges in translating these findings into clinical applications.

show abstract

siRNA and chemotherapeutic molecules entrapped into a redox-responsive platform for targeted synergistic combination therapy of glioma

Cited by 18 publications

References 32 publications

Angiopep-2-Modified Nanoparticles for Brain-Directed Delivery of Therapeutics: A Review

Angiopep-2-Modified Nanoparticles for Brain-Directed Delivery of Therapeutics: A Review

Recent Progresses in Electrochemical DNA Biosensors for SARS-CoV-2 Detection

Small Interfering RNA for Gliomas Treatment: Overcoming Hurdles in Delivery

Contact Info

Product

Resources

About